Patients with recurrent high grade gliomas treated with lapatinib monotherapy and temozolomide plus lapatinib combination to investigate the safety and efficacy of the combination.

Trial Profile

Patients with recurrent high grade gliomas treated with lapatinib monotherapy and temozolomide plus lapatinib combination to investigate the safety and efficacy of the combination.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2016

At a glance

  • Drugs Lapatinib (Primary) ; Temozolomide (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 24 May 2012 Planned number of patients changed from 74 to 66 as reported by Australian New Zealand Clinical Trials Registry.
    • 27 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top